✓ Editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Drug Reference

Zepbound

Released: Last reviewed:

Brand name for tirzepatide, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity.

By Eli Lilly
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 20, 2026 · This page is informational and does not constitute medical advice.

Zepbound overview

Brand name for tirzepatide, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity.

Zepbound at a glance

Manufacturer
Eli Lilly
FDA status
FDA-approved

Related pages

Key facts, checked November 20, 2026

The Zepbound label (effective August 28, 2026) covers weight management in adults with obesity or overweight with a related condition, and moderate to severe obstructive sleep apnea in adults with obesity. In SURMOUNT-1 (NEJM 2022), the 15 mg dose produced 20.9% average weight loss at 72 weeks (treatment-regimen estimand). Lilly’s self-pay vials start at $299 a month, a figure Lilly repeated on November 6, 2026; its full dose ladder was not re-read because lilly.com returned HTTP 403. The Medicare.gov GLP-1 Bridge page says the Bridge covers the Zepbound KwikPen only, not vials.